Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Grit Matters
Zhuhai, Guangdong, Chinagritmatters.ai ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Grit Biotechnology has advanced its lead TIL therapy program GT101 into pivotal Phase II clinical trials for solid tumors and has generated initial clinical and safety data from its CAR-NKT product in autoimmune patients. The company’s next-generation pipeline includes gene-edited TIL therapies and neoantigen cancer vaccines, with several programs approaching IND-enabling studies[1][2].
- Therapeutic areas
- OncologyImmunology
- Modalities
- Tumor-infiltrating lymphocyte therapyCell therapyGene-edited cell therapyNeoantigen cancer vaccine
- Industry
- Biotech
02
Partnerships
Vitalgen BioPharma Co., Ltd.[2]
Beyond the preview
Go deeper on Grit Matters.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Grit Matters.